| 0.2877 0.016 (5.97%) | 08-18 14:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.35 | 1-year : | 0.39 |
| Resists | First : | 0.3 | Second : | 0.34 |
| Pivot price | 0.28 |
|||
| Supports | First : | 0.25 | Second : | 0.2 |
| MAs | MA(5) : | 0.28 |
MA(20) : | 0.28 |
| MA(100) : | 0.32 |
MA(250) : | 3.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34 |
D(3) : | 43.6 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 11.8 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BGM ] has closed above bottom band by 11.2%. Bollinger Bands are 79.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 120 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.3 | 0.3 - 0.3 |
| Low: | 0.26 - 0.26 | 0.26 - 0.26 |
| Close: | 0.27 - 0.27 | 0.27 - 0.27 |
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.
Tue, 11 Aug 2026
BGM Group (BGM) seeks shareholder OK for 30-for-1 consolidation and capital hike - Stock Titan
Tue, 11 Aug 2026
BGM Group Ltd. (BGM): Investor Outlook on a Healthcare Pioneer with 88.3% Revenue Growth - DirectorsTalk Interviews
Fri, 07 Aug 2026
BGM Group Ltd (BGM) Stock News Today - TradingKey
Tue, 04 Aug 2026
BGM Group Ltd. (BGM) Stock Analysis: Navigating The Challenges In The Healthcare Sector - DirectorsTalk Interviews
Thu, 30 Jul 2026
BGM Group Ltd. Announces CEO Changes, Effective July 30, 2026 - marketscreener.com
Thu, 30 Jul 2026
BGM Group (BGM) reshapes leadership as Chen Xin resigns top roles - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 381 (M) |
| Shares Float | 133 (M) |
| Held by Insiders | 44.4 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 314 (K) |
| Shares Short P.Month | 284 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.95 |
| Profit Margin | -52.6 % |
| Operating Margin | -43.9 % |
| Return on Assets (ttm) | -3.3 % |
| Return on Equity (ttm) | -9.3 % |
| Qtrly Rev. Growth | 88.3 % |
| Gross Profit (p.s.) | 0.01 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -1.53 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 2.74 |
| Price to Cash Flow | -43.99 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 91.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|